Symbicort (budesonide/formoterol) will be used more for COPD

April 2009

Symbicort (budesonide/formoterol) will be used more for COPD.

It's now the second corticosteroid/beta-agonist combo approved for maintenance of COPD...along with Advair (fluticasone/salmeterol).

But these are NOT first-line therapies.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

proton pump inhibitors (PPIs) might DECREASE the efficacy of clopidogrel (Plavix)
Antithrombotics when and how to use vitamin K to reverse the effects of warfarin
Cardiology whether it's HARMFUL to combine an ACE inhibitor and ARB
Psychiatry how to treat dementia associated with Parkinson's
Psychiatry metabolic acidosis in patients taking the antiepileptic, zonisamide (Zonegran, etc)
Respiratory & Allergy Symbicort (budesonide/formoterol) will be used more for COPD
Respiratory & Allergy patients on Afrin or other nasal decongestants get rebound congestion
Gastroenterology Metoclopramide will have a new black box warning about the risk for tardive dyskinesia
Pediatrics Miralax is being used more to treat constipation in kids
Diabetes controversy about using glyburide for type 2 diabetes
Shortages alternatives to oxycodone
Infectious Diseases LESS cross-sensitivity between penicillins and carbapenems than most clinicians think
Gout Uloric (YOU-lor-ik, febuxostat) is the first new chronic treatment for gout in over 40 years